Evommune, Inc. | MedPath

Robust Pipeline of 50+ Therapies Reshaping Moderate to Severe Atopic Dermatitis Treatment Landscape

5 days ago

• The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition. • Recent advancements include promising biologics like rezpegaldesleukin (granted FDA fast-track designation), JAK inhibitors such as VC005 and QY201, and novel mechanisms targeting IL-4/IL-13 pathways, offering new hope for patients with inadequate response to current treatments. • Key players including Nektar Therapeutics, Corvus Pharmaceuticals, and Apogee Therapeutics are advancing clinical trials with significant milestones expected in late 2025, potentially transforming the therapeutic landscape for this chronic inflammatory skin condition.

Evommune's EVO756 Enters Phase 2 Trial for Chronic Inducible Urticaria

9 months ago

• Evommune has initiated a Phase 2 clinical trial for EVO756, a novel oral therapy targeting chronic inducible urticaria (CIndU). • The trial will evaluate EVO756's safety and efficacy in approximately 30 patients with symptomatic dermographism or cold urticaria across 15 US sites. • EVO756, a selective MRGPRX2 antagonist, aims to reduce mast cell degranulation and alleviate symptoms by blocking this receptor. • The company anticipates launching a Phase 2b trial for chronic spontaneous urticaria (CSU) in the second quarter of 2025, expanding EVO756's clinical development.